Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Peri-HCT Ruxolitinib in MF and MDS/MPN Overlap Syndromes
NCT07228624Phase 2Recruiting
- Sponsor
- Fred Hutchinson Cancer Center
- Start
- Feb 2026
- Primary completion
- Sep 2030
- Countries
- 1
01
Overview
A Phase 2 trial of ruxolitinib in graft-versus-host disease (GVHD), myelofibrosis (MF), myelodysplastic/myeloproliferative neoplasm (MDS/MPN), sponsored by Fred Hutchinson Cancer Center. Started Feb 2026; status: recruiting.
02
Drugs
03
Conditions
graft-versus-host disease (GVHD)myelofibrosis (MF)myelodysplastic/myeloproliferative neoplasm (MDS/MPN)
Beyond the preview
Go deeper on NCT07228624.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07228624.